|
|
 |
|
Viewing report
|
|
|
|
Commercial Insight: Cardiovascular and Metabolic Market Forecast
Datamonitor, Feb 2011
Antidiabetic therapies is expected to emerge as the biggest revenue earner in the cardiovascular and metabolic markets by 2019, with growth driven by a rich pipeline and new drug classes. Thrombosis has stable sales; however, the heavy genericization of the hypertension and dyslipidemia primary care markets will lead to the overall market decreasing by -0.5% in the seven major markets.
Features and benefits
- Gain insight into the cardiovascular and metabolic market potential and compare contributions from key therapy areas.
- Qualify and quantify the top 10 cardiovascular therapy brands across the seven major pharmaceutical markets from 2009 to 2019.
- Predict the future performance of leading products, classes and therapy areas.
- Assess leading drug company strategies and identify key success factors within this sector.
Highlights
- The cardiovascular and metabolic market is forecast to peak in 2011, and total market revenues will record a negative compound annual growth rate (CAGR) of -0.5% between 2009 and 2019. This is despite forecast growth in the volume consumption of cardiovascular and metabolic drugs at a CAGR of 1.8% over the same period.
- Antidiabetic therapies are forecast to become the highest revenue generators in 2019, contributing 35% of all sales in the seven major markets and 50% of cardiovascular and metabolic sales in the key US market, where other therapy areas are highly eroded by genericization.
- Merck & Co. is forecast to be the leading cardiovascular and metabolic company by 2019, driven by its blockbuster antidiabetic Januvia franchise. Novo Nordisk will grow to take second spot in 2019 due to its focus on insulin therapies and peptides that are more resistant to generic competition.
Your key questions answered
- How does the market outlook vary for diabetes, dyslipidemia, hypertension and thrombosis therapy areas until 2019?
- How will upcoming key patent expiries such as Lipitor (atorvastatin) and Plavix (clopidogrel) affect the cardiovascular and metabolic markets?
- What are the key growth classes from 2009–19, and to what extent will pipeline sales compensate for sales losses arising from key patent expiries?
- How do different regulatory and prescribing environments impact market forecasts for the US, Japan and the five major European markets?
- Who were the top company players in the cardiovascular and metabolic market in 2009 and how will the landscape change to 2019?
|
|
|
|
